IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Fine Chemicals Weekly News Round-up, April 12

4:41 AM MDT | April 12, 2012 | Alex Scott

Lonza this week disclosed that it has signed a contract to supply biotech firm Agennix (Heidelberg, Germany) with commercial quantities of Agennix's talactoferrin trial biopharma drug for treating lung cancer. The interesting fact here is that Lonza is the second European supplier. The primary supplier for the drug, which is in phase III trials, is DSM. Despite the low cost opportunities at hand to outsource production to China or India (or indeed other parts of Asia) Agennix is obviously keen to keep production close at hand in Europe. Lonza will be...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa